Tumor embolization devices market seen reaching $2.46 trillion by 2030

The Business Research Company says the tumor embolization devices market is set for steady growth through 2030 as cancer cases rise, healthcare spending increases and minimally invasive oncology expands. North America led the market in 2025, while Asia-Pacific ranked second and remains a key growth region.

Why it matters: - Tumor embolization devices are becoming a bigger part of cancer care because they can block a tumor’s blood supply or deliver therapy directly to the tumor site. - The market’s growth reflects broader demand for minimally invasive oncology tools and targeted treatment options. - Rising cancer incidence and higher healthcare spending are expected to keep supporting adoption.

What happened: - The Business Research Company released a tumor embolization devices market report covering global trends and forecasts for 2026-2035. - The market is projected to rise from $1,587.48 billion in 2025 to $1,732.02 billion in 2026. - The report forecasts the market will reach $2,464.52 billion by 2030. - The report identifies North America as the largest regional market in 2025. - Asia-Pacific ranked second in 2025 and was flagged as a major growth region.

The details: - The reported 2025-2026 growth rate is 9.1%. - The projected 2026-2030 growth rate is 9.2%. - Historical growth has been driven by wider use of interventional oncology, more solid tumor cases, more minimally invasive procedures, better catheter technologies and greater use of embolization in cancer care. - Future growth is tied to more investment in interventional oncology, stronger demand for combination cancer treatments, broader use of targeted drug delivery, greater focus on organ-sparing therapies and better integration of image-guided interventions. - The report highlights targeted embolization therapies, drug-eluting embolic agents, image-guided procedures, minimally invasive oncology interventions and precise tumor targeting as key trends. - Tumor embolization devices are specialized minimally invasive tools designed to cut off blood flow to a tumor or deliver treatment directly to the tumor site. - The report cites American Cancer Society data showing 1,958,310 new cancer diagnoses in the US in 2023, up from more than 1,918,030 in 2022. - The report also cites UK Office for National Statistics data showing UK healthcare spending rose 5.6% from 2022 to 2023, after 0.9% growth in the prior year, reaching about $317.63 billion (£292 billion) in 2023. - The market analysis also covers South East Asia, Western Europe, Eastern Europe, South America, the Middle East and Africa. - New report features include market attractiveness scoring, TAM analysis, company scoring matrix graphics and tables, Excel-based forecasting dashboards, market hotspots infographics, key technology analysis and updated graphics and tables. - The report offers a free sample at the sample request page. - The full report is available at the market report page.

Between the lines: - The forecast suggests hospitals and oncology centers are prioritizing treatments that are less invasive, more targeted and easier to integrate with imaging. - The emphasis on organ-sparing therapy and combination treatment points to a market that is moving beyond single-device use toward broader procedure-based care. - The regional split suggests mature demand in North America and more room for expansion in Asia-Pacific and other emerging markets.

What's next: - The market is expected to keep expanding through 2030 as cancer burden rises and interventional oncology becomes more embedded in care pathways. - Device makers and investors will likely focus on drug-eluting embolics, image guidance and more precise tumor targeting. - The report’s forecast implies more competition around advanced catheter systems and minimally invasive oncology workflows.

The bottom line: - Tumor embolization devices are moving from a niche oncology tool to a faster-growing category tied to rising cancer treatment demand and the shift toward minimally invasive care.